Source link : https://www.newshealth.biz/health-news/no-benefit-for-pd-1-inhibitors-in-certain-gastroesophageal-cancers-fda-panel-says/
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 expression
Author : News Health
Publish date : 2024-09-27 18:05:29
Copyright for syndicated content belongs to the linked Source.